Sodium-glucose cotransporter 2 inhibitors and neurological disorders: a scoping review.
Thahesh TharmarajaJamie S Y HoChing-Hui SiaNicole-Ann LimYao Feng ChongAmanda Y L LimRahul R RathakrishnanLeonard L L YeoVijay K SharmaBenjamin Y Q TanPublished in: Therapeutic advances in chronic disease (2022)
SGLT2i may exert neurological benefits through three mechanisms: reduction in cardiovascular risk factors, augmentation of ketogenesis and anti-inflammatory pathways. Most clinical studies were observational, meaning that a causal relationship could not be established, while randomised controlled trials were heterogeneous and powered to detect cardiovascular or renal outcomes. We suggest that a longitudinal study should be conducted and specifically powered to detect neurological outcomes.